AzTrials
AzTrials

Hemodialysis ComplicationTRIAD2NCT04554498

Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers

A study testing 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up in people with Hemodialysis Complication and Inflammation, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The primary goal of the study is to evaluate in patients on three times a week on-line HDF the efficacy, in terms of toxin removal and modulation of the inflammatory state, of two different dialyzers: Helixone versus Asimmetric cellulose triacetate (ATA). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
1 siteItaly
Study dates
1 Jan 2022to 1 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with chronic renal failure under periodic standard bicarbonate hemodialysis;
  • Three times a week dialysis session;
  • Residual diuresis <200 mL/day;
  • Age >18 years;
  • Vascular access for hemodialysis with blood flow >250 mL/minute;
  • Need of on-line hemodiafiltration (HDF) for signs of middle molecules intoxication (e.g. B2M >30 mg/L, peripheral neuropathy, cardiovascular comorbidities) or for intradialytic hypotension.

Who cannot join

  • Acute coronary syndrome;
  • Acute hemorrage;
  • Enrollment in another study protocol;
  • Active infection;
  • Malignancy;
  • Inability to provide written signed consent to participate in the study.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Nephrology Dialysis and Renal Transplantatio Unit, StOrsola University Hospital

    Bologna, 40138

    Gabriele Donati, M.D., Ph. D, +390512144054, gabriele.donati@aosp.bo.it

Other trials in Italy

About this study

The primary goal of the study is to evaluate in patients on three times a week on-line HDF the efficacy, in terms of toxin removal and modulation of the inflammatory state, of two different dialyzers: Helixone versus Asimmetric cellulose triacetate (ATA).

Read the detailed description

Patients with end-stage renal disease (ESRD) have a significantly increased cardiovascular mortality rate compared to the general population.

According to the USRDS (United States Renal Data System), in 2017 the prevalence of cardiovascular disease in the United States was 65.8% in patients with chronic kidney disease (CKD), compared to 31.9% of the subjects with stable renal function (https://www.usrds.org/2017/view/v1_04.aspx).

In the natural history of nephropathy, besides the traditional cardiovascular risk factors, an increasingly important role is played by the nontraditional factors related to uremia and dialysis treatment, namely anemia, hyperhomocysteinemia, malnutrition, hyperparathyroidism, electrolyte imbalance, and above all chronic inflammatory state and oxidative stress. The main components of dialysis-related inflammatory response include neutrophil and monocyte activation, cytokine release, oxidative stress with production of free radicals, lipid and protein oxidation, and alterations in blood redox state.

There is much evidence to indicate that ESRD patients, especially those on dialysis, are exposed to increased oxidative and carbonyl stress, that cause chemical modifications of proteins and accumulation of AGEs (advanced glycation end products).

The formation of AGEs occurs through Maillard reaction, a non-enzymatic glycation of peptide amino groups, resulting in protein structural and functional alteration and production of reactive carbonyl species .

Several studies have demonstrated a correlation between the levels of tissue AGEs and the development of various complications, since the accumulation of AGEs constitutes an index of hyperglycemia, oxidative stress and inflammation. The activation and up-regulation of the AGE receptors, including the main one RAGE (AGE Receptor), leads to the initiation of inflammatory cascades involved in the formation of atherosclerotic plaques and endothelial dysfunction, and lastly in the pathogenesis of cardiovascular disease. AGEs are also related to the thickening of the intima-media tunica of the carotid arteries, considered a marker of arteriosclerosis, as clinically confirmed by the close relationship between coronary artery disease and atherosclerotic complications in diabetes and renal failure.

Besides AGEs, a huge pattern of protein-bound toxins and of middle molecular weight uremic toxins are known to contribute to the uremic syndrome in terms of cardiovascular complications, inflammation and fibrosis . Concerning protein-bound uremic toxins, p-cresyl sulfate and indoxyl sulfate have received considerable attention recently. Among middle molecules, B2M, free light chains and FGF23 have been identified as markers of disease progression and mortality in CKD and hemodialysis.

Furthermore, the activation of leukocytes, both in response to the exposure to dialysis membranes and as a consequence of the retrotransportation of substances that promote the expression of cytokines from the dialysate, increases the release of proinflammatory cytokines, such as IL-1β, TNF-α and IL-6.

The biocompatibility and flow properties of the different filters can influence the inflammatory and oxidative response to dialysis and the levels of oxidized molecules. In general, short-term dialysis with high-flow membranes has been shown to decrease plasma levels of oxidized low-density lipoproteins, regardless of the filter material.

Nonetheless, the introduction of high-flux membranes, which increased clearance of middle molecules, appears to be inadequate to improve patient survival, as reported by two major randomized trials, the HEMO study [24] and the MPO study.

The use of on-line HDF, that combines convective and diffusive solute removal, can counterbalance the rapid decrease of middle molecule diffusion obtained with high flux hemodialysis. The integration of diffusion with convection allows a more modest sieving coefficient decrease for middle molecular weight solutes. To date, evidence from four randomized controlled trials on HDF suggests, although not definitely, that HDF with convection volumes >20 L results in better patient outcomes .

Moreover, a correlation of the membrane typology with inflammation and oxidative stress in the medium-long term was found in patients undergoing chronic dialysis treatment. A prospective study in a cohort of 50 patients who started hemodialysis with a high-flux polysulfone membrane (HF80 series, Fresenius Medical Care, St. Wendel, Germany) evaluated the variation of the inflammation and oxidative stress biomarkers. The results showed significantly increased circulating levels of IL-6, C-reactive protein (CRP) and higher carbonylation rate in dialysis patients compared to healthy controls in the first year of observation, and this trend was maintained in the following 12 months.

Successive studies investigated the long-term effects on inflammation and oxidative stress of dialysis with Helixone (Fresenius Medical Care), another type of high-flux polysulfone membrane designed to maximize the clearance of uremic toxins of average molecular weight (> 500 Daltons, Da) compared to conventional high-flux membranes. The introduction of changes as reduced hollow fiber wall thickness (≈35 μm), smaller inner diameter (≈185 μm) and higher average pore size (≈3.3 nm) has improved the clearance of medium molecular weight molecules, including β2-microglobulin (B2M), limiting the passage of larger molecules like albumin, without significant effects on inflammatory parameters .

The features of synthetic membranes related their chemical composition and the asymmetric structure of the fibers make them preferable for new highly-convective therapies, such as high-volume hemodiafiltration (HDF), only partially allowed with cellulose.

However, cellulose triacetate (CTA) and modified cellulose membranes remain the best option for the patients with hypersensitivity reactions to synthetic fibers. Although synthetic membranes, including those based on polysulfone, have a lower risk of hypersensitization than non-biocompatible ones (such as Cuprophane), in some cases adverse reactions have been reported, plausibly due to the contact between the dialyzer itself with plasma proteins and platelets.

Moreover, the choice of polysulfone membranes has been proven to affect the intracellular and serum levels of bisphenol A (BPA, molecular weight 228.3 kDa), a ubiquitous environmental toxicant found in plastic food and beverage containers, as well as in some dialyzers, with several detrimental effects. BPA is considered an endocrine-disrupting chemical that acts mainly as a female hormone: it is associated with reproductive dysfunction, immune abnormality and increased incidence of cancer. Patients on hemodialysis are a high-risk population for BPA overload, because the normal urinary elimination of the conjugated molecule decreases with low renal function. For these reasons, BPA can be thought as a uremic toxin, similarly to p-cresol, and a particular attention should be given to BPA-containing medical devices, including dialysis membranes.

Mas et al. compared BPA-free and BPA-containing dialyzers in 72 patients under on-line HDF, using a prospective 9-month, crossover study design. BPA-free dialyzers determined a greater long-term decrease in BPA levels compared to BPA-containing dialyzers, although at three months the difference was not significant. This may be due to the use of the on-line HDF technique that has been related to lower BPA levels than conventional hemodialysis.

Recently, a new generation filter in asymmetric triacetate (ATA) has been introduced, born from a technology that combines the requirements of synthetic membranes for the possibility of being used with high-volume HDF and the advantages of natural fibers (cellulose) in terms of reduced allergic reactions.

These novel ATA membranes have been demonstrated to achieve satisfactory Kt and convection volume, with good biocompatibility and inflammatory profiles, indicating them as a valuable option for patients allergic to synthetic membranes under HDF treatment.

Being tested
1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Medical subject headings
Inflammation, Toxemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-upDevice

    Also called 2) assessment of uremic toxins, inflammation and effects of patients sera in culture of endothelial cells, 3) Body impedance analysis by means of Electro fluid graph (EFG®, Akern, Pontassieve, Italia), 4) Measurement of AGEs accumulation through skin autofluorescence. (AGE Reader, DiagnOptics Technologies BV)

    1. the comparison of the effects of the two membranes on the serum levels of albumin, B2M, CRP, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-1-microglobulin (A1M), FGF23 (fibroblast growth factor 23), and inflammatory cytokines;
    2. the evaluation of the changes induced by the two filters on lymphocyte subsets, monocyte activation and senescence, and apoptosis rate;
    3. the definition of the impact of the two membranes on the accumulation of AGEs as an index of metabolic and oxidative stress, determined by a non-invasive method based on the measurement of skin autofluorescence through a dedicated device (AGE Reader, DiagnOptics Technologies BV, Groningen, Netherlands).
Study groups in NCT04554498
Study groupRoleWhat they receive
Hemodiafiltration with ATA filterExperimentalpatients with clinical history of hypersensitivity to polisulfone/poliethersulfone dialysis filters or hypersensitivity to drugs or generic allergens.
Receives: Device: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up
Hemodiafiltration with Helixone filterActive comparatorno history of hypersensitivity to polisulfone/poliethersulfone dialysis filters is assessed; no history of hypersensitivity to drugs or generic allergens is assessed.
Receives: Device: 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measurement of uremic toxins

    Beta 2 microglobulin (B2M), C-reactive protein (CRP), albumin, myoglobin, light chains, retinol binding protein, homocysteine, p-cresol, indoxyl sulfate, BPA, alpha-2-macroglobulin (A2M), FGF23 (fibroblast growth factor 23)

    Measured: 24 months. Blood samples will be drawn at Time 0 (on starting the study when the patients starts HDF treatment), after 1 month, after 3 months, after 6 months, after 12 months, and after 24 months (study end)

Secondary outcomes (8)
  1. Measurement of endothelial cells metabolism

    The patients' sera will be incubated with Human Coronary Artery Endothelial Cells (HCAECs), a human cell line isolated from normal coronary arteries. HCAECs are the ideal candidates for the study of endothelial cell functions and metabolism, proving an excellent model system to study all aspects of cardiovascular function and disease

    Measured: 24 months. Blood samples will be drawn at Time 0 (on starting the study when the patients starts HDF treatment), after 1 month, after 3 months, after 6 months, after 12 months, and after 24 months (study end)

  2. Patients survival

    the mortality rate of the patients will be recorded

    Measured: 24 months

  3. Body impedance analysis

    Body impedance analysis will be carried out monthly through Electro fluid graph machine

    Measured: 24 months.

  4. AGEs measurements

    AGEs measurements will be carried out monthly through skin autofluorescence

    Measured: 24 months

  5. Measurement of inflammatory cytokines

    measurement of interleukin 1 beta (IL-1 β), interleukin 6 (IL-6), interleukin 10 (IL-10),interleukin 12 p 70 (IL-12 (p70)), interleukin 17 (IL -17), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ)

    Measured: 24 months. Blood samples will be drawn at Time 0 (on starting the study when the patients starts HDF treatment), after 1 month, after 3 months, after 6 months, after 12 months, and after 24 months (study end)

  6. Measurement of inflammatory cell activation

    Measurement of lymphocyte subsets, monocyte activation and senescence, and apoptosis rate

    Measured: 24 months. Blood samples will be drawn at Time 0 (on starting the study when the patients starts HDF treatment), after 1 month, after 3 months, after 6 months, after 12 months, and after 24 months (study end)

  7. Infection rate

    The number of infections that affected the patients and the rate of hospitalization for infections will be recorded

    Measured: 24 months

  8. Cardiovascular diseases

    The number of cardiovascular disease that affected the patients and the rate of hospitalization for cardiovascular disease will be recorded

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2020
  2. Study start1 Jan 2022 (estimated)
  3. Primary completion1 May 2023 (estimated)
  4. Study completion1 May 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
16 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04554498
Sponsor's protocol ID
596/2019/Oss/AOUBo
Acronym
TRIAD2
Status last verified
Mar 2021
First submitted
5 Sep 2020
Last updated
17 Mar 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • O'Lone E, Viecelli AK, Craig JC, Tong A, Sautenet B, Roy D, Herrington WG, Herzog CA, Jafar T, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AYM, Wanner C, Zannad F, Winkelmayer WC, Webster AC, Wheeler DC. Cardiovascular Outcomes Reported in Hemodialysis Trials. J Am Coll Cardiol. 2018 Jun 19;71(24):2802-2810. doi: 10.1016/j.jacc.2018.04.012.

    PubMed 29903353
  • Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002 Jul;13(7):1918-27. doi: 10.1097/01.asn.0000019641.41496.1e.

    PubMed 12089389
  • Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008 Dec;4(12):672-81. doi: 10.1038/ncpneph0954. Epub 2008 Sep 30.

    PubMed 18825155
  • Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000 Apr;15(4):454-7. doi: 10.1093/ndt/15.4.454. No abstract available.

    PubMed 10727537
  • Georgatzakou HT, Tzounakas VL, Kriebardis AG, Velentzas AD, Kokkalis AC, Antonelou MH, Papassideri IS. Short-term effects of hemodiafiltration versus conventional hemodialysis on erythrocyte performance. Can J Physiol Pharmacol. 2018 Mar;96(3):249-257. doi: 10.1139/cjpp-2017-0285. Epub 2017 Aug 30.

    PubMed 28854342
  • Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int. 2002 Feb;61(2):705-16. doi: 10.1046/j.1523-1755.2002.00151.x.

    PubMed 11849414
  • McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63. doi: 10.2215/CJN.02420311. Epub 2011 Sep 1.

    PubMed 21885790
  • Kimura H, Tanaka K, Kanno M, Watanabe K, Hayashi Y, Asahi K, Suzuki H, Sato K, Sakaue M, Terawaki H, Nakayama M, Miyata T, Watanabe T. Skin autofluorescence predicts cardiovascular mortality in patients on chronic hemodialysis. Ther Apher Dial. 2014 Oct;18(5):461-7. doi: 10.1111/1744-9987.12160. Epub 2014 Jan 24.

    PubMed 24456287
  • Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res. 2004 Aug 6;95(3):233-8. doi: 10.1161/01.RES.0000137876.28454.64.

    PubMed 15297385
  • Hangai M, Takebe N, Honma H, Sasaki A, Chida A, Nakano R, Togashi H, Nakagawa R, Oda T, Matsui M, Yashiro S, Nagasawa K, Kajiwara T, Takahashi K, Takahashi Y, Satoh J, Ishigaki Y. Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence. J Atheroscler Thromb. 2016 Oct 1;23(10):1178-1187. doi: 10.5551/jat.30155. Epub 2016 Mar 10.

    PubMed 26961217
  • Wang CC, Wang YC, Wang GJ, Shen MY, Chang YL, Liou SY, Chen HC, Chang CT. Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis. PLoS One. 2016 Jan 25;11(1):e0147771. doi: 10.1371/journal.pone.0147771. eCollection 2016.

    PubMed 26809145
  • Hofmann B, Jacobs K, Navarrete Santos A, Wienke A, Silber RE, Simm A. Relationship between cardiac tissue glycation and skin autofluorescence in patients with coronary artery disease. Diabetes Metab. 2015 Nov;41(5):410-5. doi: 10.1016/j.diabet.2014.12.001. Epub 2014 Dec 29.

    PubMed 25553578
  • Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins (Basel). 2018 Jan 8;10(1):33. doi: 10.3390/toxins10010033.

    PubMed 29316724
  • Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl Sulfate. Toxins (Basel). 2017 Jan 29;9(2):52. doi: 10.3390/toxins9020052.

    PubMed 28146081
  • Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. J Am Heart Assoc. 2017 Feb 7;6(2):e005022. doi: 10.1161/JAHA.116.005022. No abstract available.

    PubMed 28174171

Questions about this trial

What is this clinical trial studying?

A study testing 1) high flux hemodiafiltration thrice -weekly during a 24 month follow-up in people with Hemodialysis Complication and Inflammation, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gaetano La Manna (+390512144577, gaetano.lamanna@unibo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measurement of uremic toxins (time frame: 24 months. Blood samples will be drawn at Time 0 (on starting the study when the patients starts HDF treatment), after 1 month, after 3 months, after 6 months, after 12 months, and after 24 months (study end)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04554498, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in